P. Ma

发表

A Selective Small Molecule c-MET Inhibitor, PHA665752, Cooperates with Rapamycin

J. Christensen, R. Salgia, P. Ma, 2005, Clinical Cancer Research.

Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells.

Ravi Salgia, Takashi Kijima, Gautam Maulik, 2002, Cancer research.

Detection of NRG1 Gene Fusions in Solid Tumors

Edward S. Kim, J. Nieva, A. Wozniak, 2019, Clinical Cancer Research.

Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer

Jae Cheol Lee, Thomas LaFramboise, Chang-Min Choi, 2012, Nature Genetics.

Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.

Ravi Salgia, Edward A Fox, Erik Schaefer, 2005, Cancer research.

RET-Rearranged Lung Adenocarcinomas with Lymphangitic Spread, Psammoma Bodies, and Clinical Responses to Cabozantinib

J. Ross, V. Velcheti, Siraj M. Ali, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Combined treatment with MET inhibitors and other therapies in lung cancer.

P. Ma, Rakesh Bagai, 2012, Translational lung cancer research.

Haptoglobin alpha-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer.

R. Salgia, P. Ma, G. Maulik, 2004, Anticancer research.

The Journey of an EGFR-Mutant Lung Adenocarcinoma through Erlotinib, Osimertinib and ABCP Immunotherapy Regimens: Sensitivity and Resistance

P. Ma, M. Mattes, A. Kibirova, 2019, Case Reports in Oncology.

P2-138: Disruption of a conserved ion pair E884-R958 in EGFR differentially alters kinase inhibitor sensitivity and downstream signaling

T. Boggon, B. Halmos, S. Dietrich, 2007 .

MET receptor juxtamembrane exon 14 alternative spliced variant: novel cancer genomic predictive biomarker.

P. Ma, 2015, Cancer discovery.

Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas

P. Ma, D. Morgensztern, B. Oronsky, 2017, Neoplasia.

Novel targets for therapeutic agents in small cell lung cancer.

R. Salgia, P. Ma, 2004, Journal of the National Comprehensive Cancer Network : JNCCN.

Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.

R. Salgia, G. Shapiro, P. Ma, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Durable Near-Complete Response to Anti-PD-1 Checkpoint Immunotherapy in a Refractory Malignant Solitary Fibrous Tumor of the Pleura

G. T. Budd, P. Ma, G. Budd, 2017, Case Reports in Oncology.

Fibronectin enhances viability and alters cytoskeletal functions (with effects on the phosphatidylinositol 3‐kinase pathway) in small cell lung cancer

R. Salgia, P. Ma, E. Schaefer, 2003, Journal of cellular and molecular medicine.

Dual MET–EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer

Deborah S. Barkauskas, B. Halmos, C. Flask, 2008, British Journal of Cancer.

Role of c-MET in upper aerodigestive malignancies--from biology to novel therapies.

T. Seiwert, S. Dietrich, P. Ma, 2005, Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer.

c-MET expression/activation, functions, and mutations in non-small cell lung cancer

M. Meyerson, W. Richards, D. Sugarbaker, 2004 .

Incidence of Neuregulin1 (NRG1) gene fusions across tumor types.

Edward S. Kim, J. Nieva, A. Wozniak, 2018 .

Therapeutic targeting of the receptor tyrosine kinase Met.

R. Salgia, P. Ma, M. Sattler, 2004, Cancer treatment and research.

Phase-II Trial of Rebeccamycin Analog, a Dual Topoisomerase-I and -II Inhibitor, in Relapsed “Sensitive” Small Cell Lung Cancer

B. Halmos, T. Mekhail, P. Ma, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Prospective Trial Evaluating the Safety and Systemic Response From the Concurrent Use of Radiation Therapy with Checkpoint Inhibitor Immunotherapy in Metastatic Non-Small Cell Lung Cancer.

P. Ma, S. Wen, M. Mattes, 2021, Clinical lung cancer.

Patterns of disease progression to checkpoint inhibitor immunotherapy in patients with stage IV non‐small cell lung cancer

P. Ma, M. Mattes, M. Almubarak, 2020, Journal of medical imaging and radiation oncology.

Special issue: "MET as actionable target in cancer therapy".

P. Ma, 2017, Annals of translational medicine.

Characterization of MET Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome Sequencing

B. Halmos, S. Dacic, P. Ma, 2022, JTO clinical and research reports.

ARQ-197, an oral small-molecule inhibitor of c-Met for the treatment of solid tumors.

P. Ma, Weiwen Fan, Rakesh Bagai, 2010, IDrugs : the investigational drugs journal.

P. Ma, J. Albandar, Samuel A Merrill, 2021, Cancers.

In vivo positron emission tomography (PET) imaging of mesenchymal-epithelial transition (MET) receptor.

P. Ma, Ruoshi Li, Changning Wang, 2010, Journal of medicinal chemistry.

Two generations of light/never-smokers with advanced adenocarcinoma of the lung with durable responses to erlotinib.

P. Ma, N. Pennell, L. Yin, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

c-Met: Structure, functions and potential for therapeutic inhibition

J. Christensen, R. Salgia, P. Ma, 2003, Cancer and Metastasis Reviews.

Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition.

R. Salgia, P. Morrison, P. Ma, 2002, Cytokine & growth factor reviews.

Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC

H. Ditzel, F. de Marinis, R. Rosell, 2017, Journal of the National Cancer Institute.

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

Funda Meric-Bernstam, Ryma Benayed, Marc Ladanyi, 2018, The New England journal of medicine.

Larotrectinib is Highly Active in Patients with Advanced Recurrent TRK Fusion Thyroid (TC) and Salivary Gland Cancers (SGC)

A. Drilon, R. Doebele, D. Hong, 2018 .

High-throughput mutational analysis of the human cancer genome.

P. Ma, Zhenghe Wang, Xiaodong Zhang, 2006, Pharmacogenomics.

Tracking MET de-addiction in lung cancer: A road towards the oncogenic target.

G. Tortora, R. Rosell, P. Ma, 2017, Cancer treatment reviews.

Therapeutic targeting of receptor tyrosine kinases in lung cancer

R. Salgia, P. Ma, N. Choong, 2005, Expert opinion on therapeutic targets.

Multi-hallmark long noncoding RNA maps reveal non-small cell lung cancer vulnerabilities

Hugo A. Guillen-Ramirez, Rory Johnson, P. Ma, 2021, bioRxiv.

Biomarker discovery in lung cancer--promises and challenges of clinical proteomics.

Ravi Salgia, R. Salgia, P. Ma, 2007, Mass spectrometry reviews.

Expression and mutational analysis of MET in human solid cancers

J. Christensen, R. Salgia, E. Vokes, 2008, Genes, chromosomes & cancer.

Navigating the “No Man's Land” of TKI-Failed EGFR-Mutated Non–Small Cell Lung Cancer (NSCLC): A Review

P. Ma, A. Oronsky, P. Cabrales, 2017, Neoplasia.

The Role of the Insulin-like Growth Factor-1 Receptor (IGF-1R), Phosphatase and Tensin Homolog (PTEN), c-Met, and the PI3-Kinase Pathway in Colorectal Cancer

P. Ma, Rakesh Bagai, 2012, Current Colorectal Cancer Reports.

c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.

R. Salgia, J. Griffin, E. Fox, 2003, Cancer research.

MET targeted therapy for lung cancer: clinical development and future directions.

P. Ma, Yan Feng, 2012, Lung Cancer.

Activated c‐Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer

R. Salgia, E. Schaefer, P. Ma, 2002, Journal of cellular and molecular medicine.

Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy

P. Ma, Zuan-Fu Lim, 2019, Journal of Hematology & Oncology.

Cancer genes in lung cancer: racial disparities: are there any?

P. Ma, Patrick C Ma, Ahmed El-Telbany, 2012, Genes & cancer.

Ethnic Differences and Functional Analysis of MET Mutations in Lung Cancer

Jie Liang, D. Nicolae, J. Minna, 2009, Clinical Cancer Research.

NTRK-Targeted Therapy in Lung Cancer

P. Ma, Xiaoliang Wu, Lin Zhu, 2019, Targeted Therapies for Lung Cancer.

MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents.

B. Halmos, C. Flask, P. Ma, 2011, Cancer research.

Quantifying EGFR alterations in the lung cancer genome with nanofluidic digital PCR arrays.

Ramesh Ramakrishnan, Jun Wang, Weiwen Fan, 2010, Clinical chemistry.

Response to pemetrexed chemotherapy in lung adenocarcinoma-bronchioloalveolar carcinoma insensitive to erlotinib.

P. Ma, G. V. Manson, 2010, Clinical lung cancer.

Clinical development of MET targeted therapy for human cancer

P. Ma, Zhe Tang, N. Tirgan, 2009 .

Gefitinib response of erlotinib-refractory lung cancer involving meninges—role of EGFR mutation

R. Salgia, M. Tretiakova, T. Seiwert, 2006, Nature Clinical Practice Oncology.

Targeting the MET receptor tyrosine kinase in non-small cell lung cancer: emerging role of tivantinib

P. Ma, E. Agwa, 2014, Cancer management and research.

Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma.

G. Gordon, D. Sugarbaker, R. Bueno, 2006, Cancer research.

Haptoglobin α-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in Small cell lung cancer

R. Salgia, P. Ma, G. Maulik, 2004 .

MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies

A. Borczuk, B. Halmos, P. Ma, 2021, Expert opinion on therapeutic targets.

Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity

J. Christensen, T. Boggon, B. Halmos, 2008, Oncogene.

Effect of a c-Met-specific, ATP-competitive small-molecule inhibitor SU11274 on human ovarian carcinoma cell growth, motility, and invasion

R. Berkowitz, J. Christensen, R. Salgia, 2007, International Journal of Gynecologic Cancer.

A Phase II Study of ABT-751 in Patients with Advanced Non-small Cell Lung Cancer

G. Gordon, P. Ma, E. Cohen, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The role of ephrins and Eph receptors in cancer.

Ravi Salgia, R. Salgia, P. Ma, 2004, Cytokine & growth factor reviews.

MET signaling: novel targeted inhibition and its clinical development in lung cancer.

P. Ma, Yan Feng, P. Thiagarajan, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion

R. Salgia, M. Tretiakova, P. Ma, 2007, British Journal of Cancer.

A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase.

J. Christensen, R. Salgia, P. Ma, 2003, Cancer research.

Next-Generation Novel Noninvasive Cancer Molecular Diagnostics Platforms Beyond Tissues.

P. Ma, Xiaoliang Wu, Lin Zhu, 2018, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

High MET Receptor Expression But Not Gene Amplification in ALK 2p23 Rearrangement Positive Non–Small-Cell Lung Cancer

R. Tubbs, P. Ma, C. Farver, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies.

D. Tenen, S. Kobayashi, T. Boggon, 2007, Cancer research.

ALK Status Testing in Non–Small-Cell Lung Carcinoma by FISH on ThinPrep Slides with Cytology Material

J. Reynolds, R. Tubbs, P. Ma, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH.

R. Tubbs, P. Ma, C. Farver, 2013, The Journal of molecular diagnostics : JMD.

Anti-MET-targeted therapy for NSCLC: has it come of age?

P. Ma, 2012 .

Anti-MET targeted therapy has come of age: the first durable complete response with MetMAb in metastatic gastric cancer.

P. Ma, Yan Feng, 2011, Cancer discovery.

Views Anti-MeT Targeted Therapy Has Come of Age : The First Durable Complete Response with MetMAb in Metastatic Gastric Cancer

P. Ma, Yan Feng, 2011 .

Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFβ2-bioenergetics-mitochondrial priming

R. Rosell, M. Veigl, D. Danielpour, 2016, Oncotarget.

Quantification of Anaplastic Lymphoma Kinase Protein Expression in Non-Small Cell Lung Cancer Tissues from Patients Treated with Crizotinib.

M. Monga, V. Velcheti, D. Krizman, 2016, Clinical chemistry.

Efficacy and Safety of Glembatumumab Vedotin in Patients With Advanced or Metastatic Squamous Cell Carcinoma of the Lung (PrECOG 0504)

S. Ramalingam, P. Ma, R. Pillai, 2021, JTO clinical and research reports.

RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer

J. Trepel, P. Ma, D. Morgensztern, 2019, British Journal of Cancer.

Personalized targeted therapy in advanced non–small cell lung cancer

P. Ma, 2012, Cleveland Clinic Journal of Medicine.

Utilization and costs of epidermal growth factor receptor mutation testing and targeted therapy in Medicare patients with metastatic lung adenocarcinoma

P. Ma, C. Belani, Chan Shen, 2022, BMC Health Services Research.

Y Chromosome LncRNA Are Involved in Radiation Response of Male Non–Small Cell Lung Cancer Cells

P. Ma, Gangqing Hu, S. Wen, 2020, Cancer Research.

AXL–GAS6 expression can predict for adverse prognosis in non-small cell lung cancer with brain metastases

P. Ma, Zhenfeng Zhang, Xingsu Yu, 2017, Journal of Cancer Research and Clinical Oncology.

Pathway in Malignant Pleural Mesothelioma Functional Analysis of c-Met / Hepatocyte Growth Factor

G. Gordon, D. Sugarbaker, R. Bueno, 2005 .

Small Cell Lung Cancer − RNA in Non Therapeutic Inhibition with SU 11274 and Small Interfering Functional Expression and Mutations of c-Met and Its

W. Richards, D. Sugarbaker, J. Christensen, 2005 .

Primary pleural epithelioid sarcoma of the proximal type: a diagnostic and therapeutic challenge.

P. Ma, M. Smolkin, Z. Ahmad, 2019, Translational Lung Cancer Research.

ADAURA: The role of adjuvant EGFR TKI and future consideration (Pro)

P. Ma, 2021 .

Acquired trichomegaly: trichomegaly secondary to erlotinib.

P. Ma, Arun D. Singh, Carlos A Medina Mendez, 2014, JAMA ophthalmology.

EGFR mutational genotyping of liquid based cytology samples obtained via fine needle aspiration (FNA) at endobronchial ultrasound of non-small cell lung cancer (NSCLC).

J. Reynolds, R. Tubbs, P. Ma, 2014, Lung cancer.

(Not Giving Up) The Marathon Race of MET Targeting Therapy: Are We There Yet?

P. Ma, 2019, Clinical Cancer Research.

Genomic and transcriptional alterations in first-line chemotherapy exert a potentially unfavorable influence on subsequent immunotherapy in NSCLC

H. Popper, R. Rosell, N. van Zandwijk, 2021, Theranostics.

Phase II trial of Sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer

B. Halmos, N. Sharma, T. Mekhail, 2014, Investigational New Drugs.

Overview of Various Techniques/Platforms With Critical Evaluation of Each

P. Ma, E. Agwa, 2013, Current Treatment Options in Oncology.

YB-1 regulates tumor growth by promoting MACC1/c-Met pathway in human lung adenocarcinoma

T. Guo, R. Rosell, P. Ma, 2017, Oncotarget.

Choroidal metastases responsive to crizotinib therapy in a lung adenocarcinoma patient with ALK 2p23 fusion identified by ALK immunohistochemistry.

R. Tubbs, P. Ma, Arun D. Singh, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Mechanisms of metastasis as related to receptor tyrosine kinases in small-cell lung cancer.

R. Salgia, P. Ma, G. Maulik, 2003, Journal of Environmental Pathology And Toxicology.

DNA damage response and repair (DDR) gene mutations and correlation with tumor mutation burden (TMB) in non-small cell lung cancer (NSCLC).

J. Nieva, H. Borghaei, Y. Boumber, 2019, Journal of Clinical Oncology.

Long Noncoding RNA SBF2-AS1 Is Critical for Tumorigenesis of Early-Stage Lung Adenocarcinoma

R. Chen, H. Popper, G. Brandi, 2019, Molecular therapy. Nucleic acids.

Genomic and immunologic characterization of large-cell neuroendocrine carcinoma of the lung.

Chul Kim, A. Wozniak, T. Owonikoko, 2021 .

OA10.03 YAP-NOTCH and STAT3 Signaling Rebound as a Compensatory Response to Gefitinib or Osimertinib Treatment in EGFR Mutant Lung Cancer

R. Rosell, A. Cardona, P. Ma, 2017 .

Targeting the MeT receptor tyrosine kinase in non-small cell lung cancer : emerging role of tivantinib eberechi

P. Ma, S. Agwa, 2014 .